Abbott Laboratories vs Medtronic ABT vs MDT

Abbott Laboratories and Medtronic on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.

Compare other stocks

ABTMDT

What differs most

generated from the numbers below

One-year price return: Medtronic −0.3%, Abbott Laboratories −17.8%.
Market value: Abbott Laboratories $181.48B, Medtronic $121.20B.
Trailing P/E: Abbott Laboratories 29.4×, Medtronic 23.3×.
Price / sales: Abbott Laboratories 4.0×, Medtronic 3.2×.

Price return

2025-10-16 → 2026-10-16

ABT−17.8%

MDT−0.3%

Prices at the close on 2026-10-16

$104.89

$94.75

Profile

latest

Sector

Healthcare

Industry

Medical - Devices

Market value

$181.48B

$121.20B

Enterprise value

$208.73B

$147.66B

Employees

115,000

95,000

Revenue per employee (TTM)

$392K

$395K

Our models

nightlythe valuation on each stock's page

Price vs model

3% undervalued vs model

4% overvalued vs model

Model range

$70.17–245

$51.30–265

Models in the headline

FCF growth priced in, at a 10% return

13.7%

15.1%

Every model, its assumptions and its range: ABT valuation · MDT valuation. The growth priced in, at any return: ABT reverse DCF · MDT reverse DCF.

Trading

close 2026-10-16

Last close

$104.89

$94.75

52-week high

$130.59

$105.35

52-week low

$82.56

$73.75

Price vs 52-week high

−19.7%

−10.1%

Price vs 52-week low

+27.0%

+28.5%

Average daily volume / shares

0.6%

1.1%

Beta

0.58

0.57

Returns

to 2026-10-16

1 month

+2.5%

+2.3%

3 months

+6.1%

+13.4%

6 months

+9.9%

+10.6%

Year to date

−16.3%

−1.4%

1 year

−17.8%

−0.3%

1 year, dividends added

−15.8%

+2.7%

2 years

−11.0%

+5.3%

Valuation

ABT price × TTM to Mar 2026 · MDT price × TTM to Jul 2026

P/E (TTM)

29.4×

23.3×

P/E on consensus EPS (next FY)

19.0×

15.9×

Price / sales

4.0×

3.2×

EV / sales

4.6×

3.9×

EV / EBITDA

—

15.2×

Price / book

3.5×

2.4×

Price / free cash flow (FY)

24.5×

22.3×

Free-cash-flow yield (FY)

4.1%

4.5%

Growth

ABT TTM and FY2025 · MDT TTM and FY2026

Revenue growth (TTM)

—

+5.8%

Revenue growth, consensus next FY

+13.5%

+7.4%

Revenue, 3-year CAGR

0.5%

5.2%

Revenue, 5-year CAGR

5.1%

3.8%

EPS growth (TTM)

—

+13.4%

EPS growth, consensus next FY

+48.3%

+60.3%

EPS, 3-year CAGR

−1.6%

9.8%

Free cash flow, 3-year CAGR

−1.8%

5.8%

Diluted shares, 3-year change

−0.9%

−3.4%

Profitability

ABT TTM to Mar 2026 · MDT TTM to Jul 2026

Gross margin (FY)†

55.5%

0.0%

Operating margin

17.1%

18.1%

EBITDA margin

—

25.9%

Net margin

13.9%

Free-cash-flow margin (FY)

16.7%

14.9%

Return on equity

12.1%

10.4%

Return on assets

5.7%

5.6%

Asset turnover

0.41

0.40

† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.

Balance sheet

ABT MRQ Mar 2026 · MDT MRQ Jul 2026

Cash

$6.80B

$1.69B

Total debt

$34.05B

$28.15B

Net debt

$27.24B

$26.46B

Debt / equity

0.7×

0.6×

Net debt / EBITDA (TTM)

—

2.7×

Interest coverage (FY)

23.6×

9.0×

Current ratio (FY)

1.58

0.00

Dividends

trailing 12 months

Dividend yield

2.4%

3.0%

Dividends per share

$2.52

$2.86

Payout ratio (of TTM EPS)

70.6%

70.4%

Dividend per share, 5-year CAGR

7.0%

3.4%

Frequency

Quarterly

Ownership and activity

last 90 days · latest 13F

Tracked superinvestors holding (13F)

Insider open-market buys (Form 4)

Insider sales (Form 4)

$46.9M

$5.9M

Analyst upgrades

Analyst downgrades

Statements

ABT income TTM to Mar 2026 · cash flow FY2025 · MDT income TTM to Jul 2026 · cash flow FY2026

Revenue

$45.13B

$37.54B

EBITDA

—

$9.72B

Operating income

$7.71B

$6.79B

Net income

$6.28B

$5.23B

EPS (diluted)

$3.57

$4.06

Operating cash flow

$9.57B

$7.33B

Capital expenditure

−$2.17B

−$1.90B

Free cash flow

$7.39B

$5.43B

Dividends paid

$4.12B

$3.64B

Keep comparing

the matchups people search for

Every ready-made comparison →

Statements from the companies' SEC filings; prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.